Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT04965688
What this trial is testing

Biology Guided Therapy for Breast Cancer for ER Positive

Who this might be right for
Breast CancerEstrogen Receptor-positive Breast CancerHER2-negative Breast Cancer
Inova Health Care Services 2
Not applicableWithdrawnNCT01695057
What this trial is testing

Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer

Who this might be right for
Stage II Breast CancerStage IIIA Breast CancerTriple-negative Breast Cancer
University of Southern California
Large-scale testing (Phase 3)Study completedNCT00785291
What this trial is testing

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+6 more
National Cancer Institute (NCI) 799
Testing effectiveness (Phase 2)WithdrawnNCT01612910
What this trial is testing

Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery

Who this might be right for
Breast Cancer Female
Barbara Ann Karmanos Cancer Institute
Testing effectiveness (Phase 2)Looking for participantsNCT07616453
What this trial is testing

Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer

Who this might be right for
HR+/HER2- Early Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 45
Testing effectiveness (Phase 2)Study completedNCT03809988
What this trial is testing

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Who this might be right for
Breast CancerAdvanced Breast CancerHormone Receptor Positive Tumor+1 more
MedSIR 198
Testing effectiveness (Phase 2)Ended earlyNCT02269670
What this trial is testing

Phase II Study of Everolimus Beyond Progression

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerProgesterone Receptor-positive Breast Cancer+5 more
Emory University 3
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Testing effectiveness (Phase 2)Study completedNCT02536742
What this trial is testing

Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
ETOP IBCSG Partners Foundation 124
Testing effectiveness (Phase 2)Temporarily pausedNCT04946864
What this trial is testing

Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Who this might be right for
Breast CancerSolid Tumor, Adult
Ascentage Pharma Group Inc. 65
Testing effectiveness (Phase 2)Study completedNCT04436744
What this trial is testing

Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

Who this might be right for
Early Breast Cancer
Hoffmann-La Roche 221
Early research (Phase 1)Active Not RecruitingNCT04993430
What this trial is testing

HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer

Who this might be right for
ER-Positive, HER2-Negative Breast Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd. 46
Large-scale testing (Phase 3)Study completedNCT02980965
What this trial is testing

Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer

Who this might be right for
Breast Cancer Female
Fudan University 249
Testing effectiveness (Phase 2)Study completedNCT00951054
What this trial is testing

NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Nippon Kayaku Co., Ltd. 61
Testing effectiveness (Phase 2)Ended earlyNCT00611715
What this trial is testing

Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.

Who this might be right for
Breast Cancer
Vanderbilt-Ingram Cancer Center 48
Early research (Phase 1)Study completedNCT06547164
What this trial is testing

Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

Who this might be right for
Healthy Participants
AstraZeneca 40
Testing effectiveness (Phase 2)Study completedNCT04588298
What this trial is testing

Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer

Who this might be right for
HER2-negative Breast Cancer
AstraZeneca 135
Testing effectiveness (Phase 2)Looking for participantsNCT06110793
What this trial is testing

Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center 56
Large-scale testing (Phase 3)Study completedNCT00630032
What this trial is testing

Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer

Who this might be right for
Breast Cancer
UNICANCER 762
Not applicableUnknownNCT05501158
What this trial is testing

CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population

Who this might be right for
Breast Cancer
Nalagenetics Pte Ltd 150
Next Page